Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cartesian Therapeutics ( (RNAC) ) has shared an announcement.
On October 2, 2025, Cartesian Therapeutics appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. Ms. Seymour brings extensive financial leadership experience from her previous roles at DNAnexus, Neogene Therapeutics, and Autolus Ltd. Her appointment includes a comprehensive employment agreement outlining her salary, bonuses, and stock options, as well as non-compete and non-solicitation clauses. This strategic hire is expected to enhance the company’s financial operations and strengthen its position in the life sciences industry.
The most recent analyst rating on (RNAC) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Underperform.
The overall stock score of 39 reflects significant financial challenges, including declining revenues, negative equity, and weak cash flows. Technical indicators show a bearish trend, and the valuation metrics highlight high risk due to unprofitability. The lack of earnings call data and corporate events further limits positive outlooks.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Cartesian Therapeutics operates in the life sciences industry, focusing on developing innovative therapies and solutions. The company is known for its contributions to the sector, particularly in advancing therapeutic approaches.
Average Trading Volume: 68,180
Technical Sentiment Signal: Sell
Current Market Cap: $260M
See more data about RNAC stock on TipRanks’ Stock Analysis page.